Cue Biopharma (CUE) Payables (2017 - 2025)

Cue Biopharma has disclosed Payables across 9 years of filings, most recently posting $3.9 million for Q4 2025.

• Payables for Q4 2025 came in at $3.9 million, up 39.85% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.9 million (up 39.85% YoY), and the FY2025 annual result was $3.9 million, up 39.85% from the prior year.
• Payables came in at $3.9 million for Q4 2025 at Cue Biopharma, up from $2.3 million in the prior quarter.
• In the past five years, Payables ranged from a high of $6.5 million in Q3 2024 to a low of $1.6 million in Q2 2022.
• The 5-year median for Payables is $2.7 million (2022), against an average of $3.0 million.
• Across the five-year window, Payables jumped 161.05% in 2024 and plunged 63.73% in 2025, its largest moves.
• Cue Biopharma's Payables stood at $2.6 million in 2021, then advanced by 5.42% to $2.7 million in 2022, then rose by 28.19% to $3.5 million in 2023, then dropped by 19.37% to $2.8 million in 2024, then jumped by 39.85% to $3.9 million in 2025.
• The last three Payables figures came in at $3.9 million (Q4 2025), $2.3 million (Q3 2025), and $3.6 million (Q2 2025), per Business Quant data.